| March 2 |
FDA Reviewing Safety of Children’s OTC Cough and Cold Medicines |
| March 5 |
FDA Takes Action to Halt Marketing of Unapproved Ergotamine |
| March 6 |
FDA Approves Tekturna for High Blood Pressure |
| March 6 |
Shires UK Launch Expands Global Reach of Fosrenol |
| March 6 |
A New Approach to Asthma Treatment Approved by Health Canada |
| March 6 |
Elsevier Acquires the Beilstein Database, World's Leading Archive
of Chemical Data |
| March 6 |
Jury Finds in Favor of ETHEX/KV on All Claims Against KV
Pharmaceutical and ETHEX Subsidiary |
| March 7 |
Wyeth and Progenics to Begin Clinical Testing of a New Formulation
of Oral Methylnaltrexone Based on Phase 2 Findings |
| March 7 |
ZymoGenetics Provides Update on rhThrombin Development Plans |
| March 7 |
Thelin (sitaxentan sodium) Receives Australian Marketing Approval |
| March 7 |
Authentix Partners with AstraZeneca to Protect Drug Supply with
Unit-Level Mass Serialisation |
| March 7 |
Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug
Discovery, Development and Commercialization Collaboration |
| March 7 |
Litigation Settlement Reached Between Tercica, Genentech and Insmed |
| March 7 |
Use of ADHD Medication Soars Worldwide |
| March 7 |
CV Therapeutics Announces Topline MERLIN TIMI-36 Results |
| March 7 |
AARP Presses Case for Rx Importation |
| March 7 |
Pharmaceutical Company Ordered to Withdraw Advertising |
| March 7 |
AARP Watchdog Report Shows Drug Prices Continue to Soar |
| March 7 |
Lipitor Receives FDA Approval for Five New Indications in Patients
With Heart Disease |
| March 7 |
Acambis Restructures Organisation to Focus Resources on Key
Programmes and Operations, and Reduce Cost Base by 20% |
| March 7 |
Insmed Announces Restructure, Settlement Ending Iplex Patent
Dispute |
| March 7 |
Publicis Groupe Announces Acquistion of Pharmagistics (USA), Leader
in Prescription Drug Compliance, Move Boosts PHCG's Technological
and Digital Expertise |
| March 7 |
African-American Doctors Say DTC Ads Improve Doctor-Patient
Relationships and Educate Patients |
| March 8 |
Algeta - Initial Public Offering |
| March 8 |
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP
by Department of Health and Human Services |
| March 8 |
The Future of BioShield in Question? |
| March 8 |
Message to Congress: Leave Canadian Prescription Drugs Alone |
| March 8 |
OncoGenex Technologies Withdraws Initial Public Offering |
| March 8 |
Nuvo Announces Further Update on Discussions With the FDA Related
to Review of Pennsaid |
| March 8 |
AARP Urges Congress to Pave Way for Generic Biologics |
| March 8 |
Senior Scientist from Johnson & Johnson Testifies Before Senate
HELP Committee on Follow-On Biologics |
| March 8 |
Novartis Leads Learning Revolution in China |
| March 9 |
Engel Publishing Partners Celebrates Its 25th Year as a Leading
Pharmaceutical Information Provider |
| March 9 |
U.S. Court of Appeals Reinstates Permanent Injunction Against
Abbott Laboratories for Infringing Innogenetics' Patent |
| March 9 |
Dorland Global Corporation Acquired by Huntsworth PLC |
| March 9 |
IMS Health Reports U.S. Prescription Sales Jump 8.3 Percent in
2006, to $274.9 Billion |
| March 9 |
FDA Sends Letter to Takeda Over Rozerem Advertisement |
| March 9 |
Roche Files Supplemental New Drug Application with U.S. Food &
Drug Administration for Tamiflu 30 mg and 45 mg Capsules |
| March 9 |
Amgen Announces Update To U.S. Prescribing Information for Aranesp
and Epogen |
| March 9 |
Galen Partners and Arena Capital Partners Complete Sale of
EduNeering Holdings, Inc., to Kaplan, Inc. |
| March 9 |
Ortho Biotech Revises Prescribing Information for Procrit (Epoetin
alfa) |
| March 9 |
PhRMA to Present Clinical Trial Exceptional Service Award |
| March 12 |
Takeda to Acquire Paradigm Therapeutics |
| March 12 |
Schering-Plough to Acquire Organon BioSciences |
| March 12 |
FDA Strengthens Safety Information for Erythropoiesis-Stimulating
Agents (ESAs) |
| March 12 |
Oxxon Therapeutics to be Acquired by Oxford Biomedica |
| March 12 |
Entelos Trading Update |
| March 12 |
Johnson & Johnson Receives Subpoenas |
| March 12 |
Cangene Receives an Approvable Letter From the FDA for Human Growth
Hormone |
| March 12 |
Protherics to Receive £10 Million Milestone from AstraZeneca |
| March 12 |
Avenue A / Razorfish Attributes Growth to Portals and Social
Network Sites as its Online Advertising Spend Increases to $542
Million |
| March 12 |
New European Approval for Xyrem Provides Significant Advance in the
Treatment of Narcolepsy |
| March 13 |
Sleeping Pill Advertisement Targeting Children Illustrates Need for Congress to Reform Prescription Drug Ads |
| March 13 |
Allegra (fexofenadine hydrochloride) Oral Suspension Now Available
to Help Manage Seasonal Allergy Symptoms In Children |
| March 13 |
Merck & Co., Inc. to Appeal Humeston Vioxx Verdict |
| March 13 |
Cellzome Receives First Milestone Payment for Alzheimer's Program
from Ortho-McNeil Pharmaceutical, Inc. |
| March 13 |
Baxter's Board of Directors Expands Share Repurchase Authorization
By $2 Billion |
| March 13 |
Pediatric Study Costs Rose Substantially from 2000 as Complexity
Grew, According to Tufts Center for the Study of Drug Development |
| March 13 |
Ecopia and Caprion Complete Combination and Announce Closing of $45
Million Private Placement: New Entity Called Thallion
Pharmaceuticals Inc. |
| March 13 |
Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:
Potential Mitigating Factors Identified which Prevent Clear
Interpretation of Results |
| March 13 |
FDA Approves Tykerb (lapatinib) in Combination With Xeloda
(capecitabine) for the Treatment of Advanced or Metastatic Breast
Cancer in Women Who Have Progressed on Prior Therapy |
| March 13 |
Illumina Announces Outcome of First Phase of Its Patent Litigation
against Affymetrix |
| March 14 |
Cancer Drug, But Not Drug Company, Praised By Networks |
| March 14 |
Baxter Holds 2007 Investor Conference in Chicago |
| March 14 |
Neuromed Receives Milestone Payment of $2 Million Under
Collaboration and License Agreement with Merck & Co., Inc. |
| March 14 |
Bristol-Myers Squibb Significantly Expands Research And Development
Presence In India Through Collaborations With Biocon And Accenture |
| March 14 |
Study of Drug Therapy for Compulsive Buying Yields a Puzzle,
Stanford Researcher Says |
| March 14 |
Maxygen Announces End of Co-Development Agreement |
| March 14 |
IR BioSciences, Inc. Responds to the Recently Cancelled Acute
Radiation Syndrome (ARS) RFP by DHHS |
| March 14 |
FDA Requests Label Change for All Sleep Disorder Drug Products |
| March 14 |
Biopartners Holdings AG Purchased by Bioton S.A. |
| March 14 |
Consona Corporation (M2M Holdings, Inc.) Closes on Acquisition of
KNOVA Software, Inc. |
| March 14 |
Eli Lilly and Company CEO Says Biomedical Breakthroughs Are
Transforming Medicine and Promise to Radically Ease the Impact of
Aging |
| March 15 |
Synovics Pharmaceuticals Signs Letter of Intent to In-License OTC
Generic Version of Omeprazole |
| March 15 |
ALTANA 2006: Eleventh Record Year in Succession with Strong Growth
in Sales and Earnings |
| March 15 |
FDA Extends Marketing Exclusivity for Levaquin |
| March 15 |
Eli Lilly Withdraws Its Marketing Authorization Application for
Arxxant |
| March 15 |
VaxGen Files Notice of Appeal Regarding Cancelled Anthrax Contract |
| March 15 |
New Human Cell-Produced Treatment for Anaemia Associated with
Chronic Kidney Disease Now Available |
| March 15 |
2006 a Record Year for Bayer |
| March 15 |
Med Ad News’ March Issue Profiles 93 New Medicines Approved
in 2006, Selects the Best New Medicine, and More |
| March 15 |
Statement of Senator Edward M. Kennedy Hearing on Drug Safety and
User Fees |
| March 16 |
FDA Clears Rapid Test for Meningitis |
| March 16 |
Tripos Shareholders Vote to Sell Discovery Informatics Business and
Liquidate Company |
| March 16 |
Trimeris and Roche Amend Research Agreement Covering
Next-Generation HIV Fusion Inhibitors |
| March 16 |
NeuroSearch Responds to Conclusions About Tesofensine Made by
BiotekAnalyse Weekly |
| March 16 |
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date
for Frova sNDA |
| March 16 |
CDC Releases Safety Data on Rotavirus Vaccine Reported
Intussusception Cases Fall Within Expected Range |
| March 16 |
FDA Approves Alexion's Soliris for All Patients With PNH |
| March 19 |
Curecumin May Be an Effective Treatment for Prostate Cancer |
| March 19 |
Evotec and Boehringer Ingelheim Enter Into Target Discovery
Collaboration in Alzheimer's Disease |
| March 19 |
Update: FDA Approves Alexion's Soliris for All Patients With PNH |
| March 19 |
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet
Primary Endpoint |
| March 19 |
Medivir Receives Shares and Cash Payment from Epiphany Biosciences |
| March 19 |
Social Networks Impact the Drugs Physicians Prescribe According to
Stanford Business School Research |
| March 19 |
Beijing Med-Pharm Corporation Signs Definitive Agreement for the
Acquisition of Majority Interest in Shanghai Rongheng
Pharmaceutical Co., Ltd. |
| March 19 |
Auriga Laboratories Sales Force Doubles Again to 200 Associates
Since January |
| March 19 |
Shire Announces Expiration of Hart-Scott-Rodino Waiting Period |
| March 19 |
AtheroGenics Reports ARISE Trial Results for AGI-1067 |
| March 19 |
Inyx Reports Update on Corporate Matters |
| March 19 |
WellPoint Expands GenericSelect Program to Include Generic Version
of Blockbuster Cholesterol-Lowering Treatment Zocor |
| March 19 |
IMS Health Acquires ValueMedics Research in the U.S., Extending
Capabilities to Demonstrate Value of Medicines |
| March 20 |
Hold the Pickles and the Penicillin: Leading Food-Service Company to Serve Antibiotic-Free Hamburgers Nationwide |
| March 20 |
Cetero Research Acquires Allied Research International, Gains
Specialty Clinical Experience |
| March 20 |
InterMune Updates Expense Forecasts and Development Plans |
| March 20 |
3SBio Inc. Announces Addition to Product Portfolio |
| March 20 |
Astellas Receives and FDA Action Letter for Prograf sNDA |
| March 20 |
Takeda's New Structure for Pharmaceutical Marketing Division in
Japan |
| March 20 |
Takeda Submits a European Marketing Authorization Application for
Ramelteon, a New Treatment for Insomnia |
| March 20 |
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for
Psychotic Major Depression Misses Primary Endpoint |
| March 20 |
Medical Discoveries Inc. Engages Strategic Advisor to Explore
Alternatives |
| March 20 |
Taro Files 2005 Form 20-F Following Completion of 2005 Audit |
| March 20 |
Barr Confirms Filing an Application with a Paragraph IV
Certification for Abilify Tablets |
| March 20 |
New Data from the US and Japan Support: No Established Causal Link
Between Neuropsychiatric Symptoms and Treatment with Tamiflu US
Databases Indicate Psychiatric Symptoms Lower in Influenza Patients
Taking Tamiflu Versus Those Not Taking Tamiflu |
| March 20 |
New Cancer Practice Guidelines Recommend Noxafil (Posaconazole) for
Antifungal Prophylaxis in Certain High-Risk Patients |
| March 20 |
New Treatment Option for Epilepsy Patients With One of the Most
Debilitating Seizure Types |
| March 20 |
Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva |
| March 21 |
Merck Initiates Squeeze Out Procedure for Shares of Merck Serono
S.A. |
| March 21 |
AstraZeneca Inaugurates State-of-the-Art Global Process R&D lab
in Bangalore |
| March 21 |
IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in
2006, to $643 Billion |
| March 21 |
Tripos Completes Sale of Discovery Informatics Business to Vector
Capital Corporation |
| March 21 |
Disclosure Laws Provide Only Limited View of Pharmaceutical Company
Payments to Physicians |
| March 21 |
PhRMA Statement on JAMA Article |
| March 21 |
Teva Provides Update on Generic Celebrex Litigation |
| March 21 |
Adderall XR - Shire Files Suit Against Colony Pharmaceuticals,
Inc., Actavis, Inc. and Actavis Group hf |
| March 21 |
FDA Proposes New, Tougher Procedures for Membership on Advisory
Committees |
| March 22 |
Conceivex At-Home Conception Kit Puts Couples in Control of Their Fertility |
| March 22 |
Eisai To Acquire Morphotek |
| March 22 |
Dey, L.P. Reaches Settlement with State of Hawaii on Pricing
Litigation |
| March 22 |
Cubist Pharmaceuticals Licenses Rights for Development and
Commercialization of Cubicin in Japan to Merck & Co., Inc. |
| March 22 |
PDI, Inc. Comments on Status of a Substantial Contract Sales
Program |
| March 22 |
Reps. Dingell, Stupak Call on Amgen, Johnson & Johnson to
Suspend Direct-to-Consumer Marketing for Anemia Drugs |
| March 22 |
Bayer Schering Pharma Presents Innovations in Men's Healthcare at
the 22nd Annual Meeting of the European Association of Urology
(EAU) |
| March 22 |
U.S. District Court Grants Permanent Injunction Prohibiting Mylan
from Marketing Generic Version of Topamax |
| March 22 |
Acomplia (rimonabant) is Now Officially Reimbursable in France, for
the Treatment of Eligible Obese and Type 2 Diabetic Patients |
| March 22 |
GSK Announces Nationwide Availability of Once-A-Day Coreg CR for
the Treatment of Three Key Cardiovascular Conditions |
| March 22 |
GSK Giving Figures Exceed £300m for Fourth Year Running:
Medicines for Lymphatic Filariasis Elimination Valued at £16
Million |
| March 22 |
Pharmacist, Patient Groups Call for Inquest into B.C.
Counterfeit-Pills Death |
| March 22 |
VASTox plc Acquires DanioLabs Ltd and Dextra Laboratories Ltd to
Strengthen Its Drug Discovery Pipeline and Pharmaceutical Services
Business |
| March 22 |
PEDIATRIC DRUG RESEARCH:Studies Conducted under Best
Pharmaceuticals for Children Act |
| March 22 |
DRUGSAFETY: FDA Needs to Further Address Shortcomings in Its
Postmarket Decision-making Process |
| March 23 |
AstraZeneca Names Shanghai Site As Initial Base for New Innovation
Centre China |
| March 23 |
NovaDel's European Formulation of Ondansetron Targeted for U.S.
Zensana |
| March 23 |
CDC Finalizes Advisory Panel Recommendations for Gardasil, Merck's
Cervical Cancer Vaccine |
| March 23 |
Amgen Discontinues Vectibix Treatment in PACCE Trial Evaluating
Vectibix as Part of Triple Combination Regimen |
| March 23 |
Hana Biosciences Provides Pipeline Update |
| March 23 |
Sen. Durbin Amendment to Delay Potential Cuts in Medicaid Payments
to Hospitals Nationwide Successfully Addded to Supplemental
Spending Bill |
| March 23 |
Procognia Enters Protein Kinase Array Collaboration With GSK |
| March 23 |
Pfizer Statement in Response to Appeals Court Decision in Norvasc
Patent Case |
| March 23 |
Pozen Announces Trexima (Sumatriptan Succinate and Naproxen Sodium)
Amended Response Accepted for Review by FDA |
| March 23 |
Leukemic Cells Find Safe Haven in Bone Marrow |
| March 23 |
Marketing Authorisation Application for Ambrisentan Validated by
European Medicines Agency |
| March 23 |
Genentech to Provide Business Update at Annual Investment Community
Meeting |
| March 23 |
UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid
Arthritis in the US |
| March 23 |
Flamel Technologies Welcomes Nationwide Availability of Coreg CR |
| March 23 |
Dalton Medicinal Chemistry Partners and Boehringer Ingelheim
(Canada) Ltd. enter into a Medicinal Chemistry Agreement |
| March 23 |
European Medicines Agency Statement on Safety of Tamiflu |
| March 23 |
Avicena Clarifies Description of Creatine Versus PD-02, Company's
Lead Drug Compound Used in NIH Phase III Clinical Trial in
Parkinson's Disease |
| March 23 |
Mylan Laboratories Launches Amlodipine Besylate Tablets and Has
Triggered Its 180 Days of Exclusivity |
| March 23 |
Advancis Pharmaceutical Resubmits New Drug Application for
Once-Daily Amoxicillin PULSYS |
| March 26 |
Mylan Announces Another First to Market With the Launch of
Ciprofloxacin Extended-Release Tablets |
| March 26 |
Arrowhead to Form New Nanomedicine Subsidiary and Acquire
Nanotherapeutics Company, C Sixty, Inc. |
| March 26 |
First Study To Show Positive Benefit On Atherosclerosis For People
With Early Signs Of Diseased Arteries |
| March 26 |
Abbott Announces Positive Six-Month Results From the World's First
Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent |
| March 26 |
Bayer Deal with Novartis Improves Profit Outlook for Betaseron
Franchise |
| March 26 |
Abbott's Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial |
| March 26 |
Novartis to Launch Its Own Branded Version of a Leading Multiple
Sclerosis Therapy Through Agreement with Bayer Schering Pharma |
| March 26 |
Insmed Withdraws Its Marketing Authorisation Application for Iplex |
| March 26 |
Genta Announces Expectation of a Negative Opinion from the CHMP on
Genasense Application for Advanced Melanoma |
| March 26 |
Januvia Approved in the European Union for the Treatment of Type 2
Diabetes |
| March 26 |
Asahi Kasei Pharma Corporation and Eisai Co., Ltd. Signed License
Agreement for Vasodilator Eril in Korea |
| March 26 |
Rimonabant USA: Update |
| March 26 |
Schering-Plough and Merck to Develop Another New Cholesterol
Lowering Medicine |
| March 26 |
Herceptin Receives Positive Opinion in Europe for Use in
Combination with an Aromatase Inhibitor for the Treatment of
Patients with Her2- and Hormone Receptor-positive Metastatic Breast
Cancer |
| March 26 |
Rimonabant USA: Update |
| March 26 |
Scios Announces Results From Exploratory Nesiritide Study Providing
Important New Renal and Mortality Safety Data with a Neutral Effect
on the Primary Endpoint |
| March 26 |
Everest Data on Short- and Long-Term Use of Otsuka's
Investigational Novel Treatment, Tolvaptan, Published in Journal of
the American Medical Association and Featured in ACC's Late
Breaking Clinical Trials |
| March 26 |
Cholesterol Drug Fails to Slow Progression of Coronary Disease,
Cleveland Clinic Study Reports |
| March 26 |
Wyeth Receives FDA Approval for New BeneFIX Features That Provide
Hemophilia B Patients a Simpler and More Convenient Preparation
Process for Recombinant Factor IX |
| March 26 |
Shire Announces Posting of Circular, Date of Extraordinary General
Meeting and Extension of Tender Offer for New River Shares Until
April 17, 2007 |
| March 26 |
Study: Identical Doses of BiDil Components Are Not Bioequivalent to
the Fixed Dose Combination-BiDil-Used in A-HeFT |
| March 26 |
Roche Submits Application to the FDA for use of Xelox (Xeloda plus
oxaliplatin) With or Without Avastin for the Treatment of Advanced
Colorectal Cancer |
| March 26 |
EvoGenix Achieves Milestone in Collaboration with GlaxoSmithKline |
| March 26 |
European Union CHMP Recommends Approval of First and Only Biologic
Treatment for Pediatric Crohn's Disease: Remicade |
| March 27 |
U.S. District Court Enjoins the FDA from Approving Additional
Amlodipine Besylate ANDAs |
| March 27 |
Replidyne Defines Preliminary Phase III Development Plan for
Faropenem |
| March 27 |
BioCryst Provides Fodosine Update |
| March 27 |
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers
with Public Shell; New Company to Develop and Market Drugs for
Disorders of the Eye |
| March 27 |
BrainCells and Lundbeck Form CNS Drug Research Collaboration |
| March 27 |
FDA MedWatch-KETEK telithromycin) Dear Healthcare Professional
letter issued re: safety related labeling changes |
| March 27 |
Lipitor Provides Unprecedented Cardiovascular Risk Reductions in
Diabetes Patients with Metabolic Syndrome and in Stroke Patients |
| March 27 |
Boehringer Ingelheim Grows Faster Than the Market Once Again -
Spiriva, Micardis and Flomax/Alna the Top Products |
| March 27 |
Seattle Genetics Announces Extension of Antibody-Drug Conjugate
Collaboration with Genentech |
| March 27 |
NICE Alzheimer's Treatment Decision Subject to Judicial Review |
| March 27 |
Heart Intervention Doesn’t Outweigh Medicine in Study |
| March 27 |
Merck Wins Product Liability Case in Madison County, Ill. -
Schwaller v. Merck |
| March 27 |
Lipitor Significantly Lowered Hospitalization Costs for Patients
with Heart Disease, Two New Analyses Show |
| March 28 |
Sanofi-aventis and Oxford BioMedica Enter Global Licensing
Agreement to Develop and Commercialise TroVax For Cancer |
| March 28 |
Cell Signaling Technology Announces Alliance with Merck to Provide
PhosphoScan Proteomics & Antibody Development for Biomarker
Discovery to Support Oncology Therapeutic Programs |
| March 28 |
Calcium Channel Blocker Adalat GITS Offer Additional Benefits |
| March 28 |
Pharmacopeia Earns Milestone Payment From Schering-Plough As Novel
Therapeutic Candidate Enters Phase 1 Clinical Trial |
| March 28 |
CSL Therapy That Mimics “Good” Cholesterol May Reduce
Plaque Volume in Coronary Arteries |
| March 28 |
Merck & Co., Inc. and Lundbeck Discontinue Joint Development
Program for Gaboxadol, an Investigational Compound for Insomnia |
| March 28 |
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to
Include Ezetimibe Efficacy Data |
| March 28 |
Clinical Development Initiated on Lead Compound in NicOx’
Glaucoma Collaboration with Pfizer |
| March 28 |
MorphoSys and Astellas Enter Antibody Partnership |
| March 28 |
Beijing Med-Pharm Corporation Signs Definitive Agreement for the
Acquisition of Majority Interest in Shanghai Rongheng
Pharmaceutical Co., Ltd. |
| March 28 |
FDA MedWatch: Accutane (isotretinoin)- Webpage Warning Against
Buying Product and Generic Versions On Line |
| March 29 |
VWR International, Inc. Acquires Remaining Stake in KMF Laborchemie
Handels GmbH |
| March 29 |
NicOx Announces that Pfizer has Disclosed Further Details of
Glaucoma Trial for PF-03187207 |
| March 29 |
CuraGen Announces Definitive Agreement to Sell 454 Life Sciences to
Roche |
| March 29 |
Avastin Approved in Europe for First Line Treatment of Women with
Metastatic Breast Cancer |
| March 29 |
Ad hoc Release According to Section 15 WpHG |
| March 29 |
Cytori To Raise $6.0 Million in Strategic Equity Agreement with
Green Hospital Supply |
| March 29 |
KV Pharmaceutical Updates Metoprolol Succinate Application Status |
| March 29 |
NeoPharm Reports on FDA Meeting |
| March 29 |
Avanir Pharmaceuticals Provides Business Update and Announces
Restructuring Plan |
| March 29 |
Roche Acquires 454 Life Sciences to Strengthen Presence in
Ultra-Fast Gene Sequencing |
| March 29 |
R&D Directions’ March Issue Profiles 100 Great
Investigational Drugs, Talks with Pfizer’s President of
Global Research & Development, and More |
| March 29 |
MedImmune Licenses Reverse Genetics Technology to sanofi pasteur
for Use in Influenza Vaccine Production |
| March 29 |
Study Sheds Light on Medication Treatment Options for Bipolar
Disorder |
| March 29 |
Athersys Successfully Advancing Multiple Commercial Collaborations |
| March 29 |
GlaxoSmithKline Submits Biologics License Application to U.S. Food
and Drug Administration for Cervarix |
| March 30 |
Progenics and Wyeth Announce Submission of New Drug Application for
the Subcutaneous Formulation of Methylnaltrexone for the Treatment
of Opioid-Induced Constipation in Patients Receiving Palliative
Care |
| March 30 |
Astellas Licenses Regeneron's Velocimmune Technology for
Discovering Human Monoclonal Antibodies |
| March 30 |
FDA Announces Voluntary Withdrawal of Pergolide Products |
| March 30 |
Dendreon Announces FDA Advisory Committee Reviewed Provenge for
Hormone Refractory Prostate Cancer |
| March 30 |
GlaxoSmithKline Files Meningococcal Conjugate Vaccine |
| March 30 |
Xeloda Approved in Europe for the Treatment of Advanced Stomach
Cancer |
| March 30 |
European Medicines Agency Recommends Restricted Use and
Strengthened Warnings for Ketek |
| March 30 |
LG Life Sciences and Takeda Announce Collaboration for Anti-Obesity
Drugs |
| March 30 |
CanBas and Takeda to Sign the Collaboration Agreement for
Investigational Compounds for Treatment of Cancer |
| March 30 |
Takeda to Obtain Development and Commercial Rights for R-851 from
3M |
| March 30 |
Galapagos Announces Achievement of Milestones Totaling €3.2
Million in Osteoarthritis Alliance with GlaxoSmithKline |
| March 30 |
Completion of the Acquisition of CellCyte Genetics Corporation (WA) |
| March 30 |
Novartis Suspends US Marketing and Sales of Zelnorm In Response to
Request from FDA |
| March 30 |
New Chemistry Approach Promises Less Expensive Drugs |
| March 30 |
Amicus Therapeutics Files For Initial Public Offering |
